Brian Buntz is a journalist at various prominent outlets including Medical Design & Outsourcing and TED Conferences. He covers a range of topics centered around science, applied sciences, medicine and healthcare, as well as advancements in pharmaceuticals and healthcare technology, with a particular focus on AI and machine learning. Brian's work has been featured in esteemed publications such as MassDevice, Drug Discovery & Development, and The Robot Report.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Brian Buntz's articles primarily focus on the healthcare and pharmaceutical industry, with a strong emphasis on data-driven insights. His coverage suggests an interest in topics such as pharmaceutical innovation, M&A activity, emerging trends in drug approvals, and AI applications within healthcare.
Given his reliance on citing data and press releases, Brian may be interested in pitches that provide comprehensive data analysis or newsworthy findings related to pharmaceuticals, medical research advancements, or trends in healthcare technology. Additionally, he might be open to receiving press releases announcing significant developments within the healthcare and pharmaceutical sectors.
While Brian's geographic focus is not specified, his coverage appears to encompass global perspectives on the healthcare and pharmaceutical industry. Therefore, relevant pitches should consider international implications or broader industry trends rather than focusing solely on specific regional matters unless they have global significance.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Brian Buntz
After securing $65 billion in Series H funding and achieving a $965 billion post-money valuation, Anthropic has filed for an IPO to access more capital. Today, the company floated the idea of a pause on model development. “We believe it would be good for the world to have the option to slow or temporarily pause frontier AI development,” the company wrote in a blog.
By: Brian Buntz
Agentic AI company Owkin and Sanofi have extended their collaboration with a five-year license for K Pro, Owkin’s AI scientist, under which Owkin will lead the end-to-end development of novel, purpose-built biopharma agents for Sanofi. Owkin pitches K Pro as a system that reasons over biological data and orchestrates AI agents to run research and…
By: Brian Buntz
Right now, more than 5,000 potential rare disease treatments are sitting on drug company shelves, according to Children's Tumor Foundation (CTF) CEO Annette Bakker. That includes drug candidates that companies have stopped actively developing, often after substantial preclinical, toxicology or early clinical work. Nonprofit organizations can help close the gap.
By: Brian Buntz
OpenAI updates GPT-Rosalind, its life sciences model, folding in GPT-5.5's agentic tools and claiming gains in medicinal chemistry, genomics and wet lab work.
By: Brian Buntz
Trump's two new AI directives cover pre-release model review and military use, while the White House floats a government ownership stake in frontier AI firms.
By: Brian Buntz
Since April 2026, AI labs have begun keeping their most powerful models behind vetted-access programs. Anthropic limited its Claude Mythos system and OpenAI its GPT-5.5-Cyber to approved security partners, each billed as able to spot and exploit software flaws with unprecedented precision. Also in April, OpenAI announced its GPT-Rosalind life-sciences model, gating it over biosecurity…
By: Brian Buntz
| American Diabetes Association's annual meeting to announce that its investigational triple agonist retatrutide can treat the conditions obesity drives, beyond the excess weight itself.
By: Brian Buntz
Remepy's Hybridopa pairs carbidopa-levodopa with an AI-driven app and cleared a Phase IIa Parkinson's trial, nearly doubling the drug's effect on the MDS-UPDRS.
By: Brian Buntz
MBARI’s Monterey Accelerated Research System (MARS) connects seafloor instruments to shore through a roughly 51-kilometer power and fiber-optic cable (red line) ending at a node about 891 meters down. The Geo-Sense system described in the new paper takes the opposite approach. That is, a portable, battery-powered cable that records locally with no link to shore. Researchers used MARS’s own fiber data to cross-check Geo-Sense’s earthquake detections. Credit: MBARI
By: Brian Buntz
| For years, many small-molecule teams have treated comprehensive Absorption, Distribution, Metabolism and Excretion (ADME) profiling as a lead-optimization step.
